Rituximab combined with a TNF inhibitor and methotrexate shows no safety signal in RA treatment
Wednesday, March 9, 2011 - 13:40
in Health & Medicine
A recent trial of rituximab in combination with a tumour necrosis factor (TNF) inhibitor and methotrexate (MTX) in patients with active rheumatoid arthritis (RA) found the safety profile to be consistent with other RA trials with TNF inhibitors. While the trial reported no new safety risks, clear evidence of an efficacy advantage in RA patients receiving the combination therapy was not observed in this study sample. Results of the trial are published in the March issue of Arthritis and Rheumatism, a peer-reviewed journal of the American College of Rheumatology...